events
16 September 2019
Da Volterra attending CICON 2019 in Paris on Sept. 25-28!
CICON 2019 is the 5th International Cancer Immunotherapy conference, the reference meeting for scientists, clinicians, regulators, drug developers, and patient…
The US Patent and Trademark Office has recently granted a new patent for Da Volterra in the USA. The patent was issued under number 10,052,288 and relates to DAV132, our phase 2 asset to protect the intestinal microbiota from antibiotic-induced disruption.
This new patent reinforces our intellectual property portfolio and comes as a complement to the already 100+ patents protecting our products worldwide.
